DTR chimeras.

To overcome this problem, Hochweller et  al. [9] used a bacterial artificial chromosome approach to express a DTR transgene regulated by the CD11c locus control region (CD11c.DOG mice, Table 1), which allows for tighter restriction of DTR expression to CD11c+ cells. CD11c.DOG mice tolerate multiple DT injections, thus making them a better-suited model for long-term depletion studies. Although CD11c.DTR and CD11c.DOG mice have proven useful to study DC biology, it is important to mention that CD11c expression is not restricted to DCs. Indeed, CD11c is also found on some macrophages, plasmablasts, activated T cells, NK cells, and Ly-6Clow FK228 price monocytes and many of these cell populations are depleted in both CD11c.DTR and CD11c.DOG mice upon DT injection [6, 9, 10]. In fact, CD11c.DTR mice have, in some instances, been used as a tool not to deplete DCs but macrophages [11]. To overcome this lack of DC-restricted expression, another cDC-depletion mouse model has recently been generated, in which a DTR transgene is inserted into the 3′ untranslated region of the Zbtb46 (zDC) gene (zDC.DTR mice, Table 1) [12]. In the immune system, Zbtb46 gene expression

appears to be restricted to cDCs and certain activated monocytes. Zbtb46 is not expressed by pDCs, macrophages or other immune cells [12, 13], making it a suitable candidate for cDC depletion. Consequently, in zDC.DTR mice injected with DT, only cDCs and, likely, some activated monocytes are depleted. However, a single injection

SCH727965 purchase of DT is lethal in these mice, probably due to Zbtb46 expression in committed erythroid progenitors and endothelial cells, in addition to its expression on cDCs [13]. As such, Vildagliptin similar to the situation with CD11c.DTR mice, cDC ablation studies in zDC.DTR mice necessitate the use of radiation chimeras generated by reconstitution of wild-type mice with zDC.DTR bone marrow. Such chimeras consequently suffer from the limitation of the lack of depletion of the radioresistant DC subsets. Several other DTR mouse models have been generated with the purpose of inducibly depleting specific DC subsets rather than all DCs (Table 1). Two groups independently generated mice in which a DTR-containing transgene was inserted into the Langerin locus, either via a knock-in approach or insertion into the 3′ untranslated region [14, 15]. While Langerin is predominantly expressed on LCs, it is also expressed on certain dermal DCs and other lymphoid tissue DC populations. Therefore, DT treatment of Langerin.DTR mice not only ablates LCs, but also a fraction of dermal DCs. This problem can be overcome by critically timing experiments after a single DT injection, as dermal DCs start to reappear as early as day 5, while LCs remain depleted for more than 2 weeks [15, 16].